NCT01747512 is a Phase 2 clinical trial of C-PERT in Thyroid Neoplasms, sponsored by AHS Cancer Control Alberta.

Who is sponsoring NCT01747512?

NCT01747512 is sponsored by AHS Cancer Control Alberta.

What drugs are being tested in NCT01747512?

Interventions in NCT01747512: C-PERT, G-PERT.

What condition does NCT01747512 study?

NCT01747512 studies Thyroid Neoplasms, Head and Neck Neoplasms.

Is NCT01747512 still recruiting?

NCT01747512 is currently withdrawn. Last updated 10 November 2017.

Last reviewed 2017-11-10 · How we verify

NCT01747512

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Phase II/III Study of Cyclotron-produced Tc-99m Pertechnetate (C-PERT) Efficacy and Safety in Patients With Conformed and Suspected Thyroid Cancer or Head and Neck Cancer

Withdrawn Phase 2 Last updated 10 November 2017

What this trial tests

Phase 2 trial testing C-PERT in Thyroid Neoplasms. Withdrawn.

Quick facts

Lead sponsor	AHS Cancer Control Alberta
Phase	Phase 2
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	diagnostic
Primary completion	1 May 2013

Drugs / interventions tested

C-PERT — full drug profile →
G-PERT — full drug profile →

Conditions studied

Thyroid Neoplasms — all drugs for Thyroid Neoplasms →
Head and Neck Neoplasms — all drugs for Head and Neck Neoplasms →

Sponsor

AHS Cancer Control Alberta — full company profile →

Who can join

Adults 18 to 79, any sex, with Thyroid Neoplasms or Head and Neck Neoplasms. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

To demonstrate the efficacy of C-PERT (manufactured by the Edmonton PET Centre/ERC) in comparison to G-PERT (fromm approved commercial sources) using qualitative and quantitative clinical imaging biodistribtion data.
Time frame: 5 months

Sponsor's own description

Doctors at the Cross Cancer Institute have developed a new method of producing 99mTc Pertechnetate in a cyclotron unit. A study done at the Cross Cancer Institute in 2011 with ten patients using this imaging agent showed that it was safe and produced images with the same pattern as generator produced Pertechnetate. This study is now being done in larger numbers of patients to again show that the imaging pattern of both agents is the same, and to again demonstrate its safety.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Thyroid Neoplasms

Currently open trials in the same condition.

NCT07419932 — Response to Neoadjuvant Treatment in Locally Advanced Thyroid Cancer · recruiting
NCT07447089 — EMDR Integrative Group Protocol and Individual Treatment for Patients With Cancer: A Pilot Study · NA · recruiting
NCT07010380 — Dual-Channel Near-Infrared Autofluorescence Imaging and AI Analysis to Locate Parathyroid Glands (PTFinder) · recruiting
NCT07434206 — Safety and Efficacy of Dexmedetomidine in Controlling Hemodynamics During Resection of Active Thyroid Secreting Tumors · Phase 2, PHASE3 · active not recruiting
NCT06398795 — Dual-port Trans-subclavian Thyroid Endoscopic Surgery · NA · recruiting

Other AHS Cancer Control Alberta trials

Trials by the same sponsor.

NCT05128734 — Temozolomide Monotherapy or in Combination With Olaparib in Patients With Triple Negative Breast Cancer (TNBC) · Phase 2 · not yet recruiting
NCT06860542 — Inhaled Budesonide for REcurrence Prevention and Adjuvant THerapy in Checkpoint Inhibitor Pneumonitis · Phase 2 · recruiting
NCT05345847 — Steroid Sparing in Immune Related Hepatitis (irH) · NA · recruiting
NCT05407987 — Ferric Derisomaltose and Outcomes in the Recovery of Gynecologic Oncology: ERAS (Enhanced Recovery After Surgery) · Phase 3 · recruiting
NCT05421416 — Loratadine for the Prevention of G-CSF-related Bone Pain · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01747512 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by AHS Cancer Control Alberta
Last refreshed: 10 November 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01747512.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing